BIIB132 + BIIB132-Matching Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Ataxia Type 3
Conditions
Spinocerebellar Ataxia Type 3
Trial Timeline
Feb 2, 2022 → Jul 25, 2023
NCT ID
NCT05160558About BIIB132 + BIIB132-Matching Placebo
BIIB132 + BIIB132-Matching Placebo is a phase 1 stage product being developed by Biogen for Spinocerebellar Ataxia Type 3. The current trial status is terminated. This product is registered under clinical trial identifier NCT05160558. Target conditions include Spinocerebellar Ataxia Type 3.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05160558 | Phase 1 | Terminated |
Competing Products
15 competing products in Spinocerebellar Ataxia Type 3
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| IVIG | Baxter | Phase 2 | 49 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 60 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |
| troriluzole + Placebo | Biohaven | Phase 3 | 72 |